[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 8 days · First seen · Last updated

Biopharmaceutical manufacturing expansion in Songdo

Overview

Biopharmaceutical manufacturing capacity is expanding within the Songdo Bio Cluster in South Korea.

Celltrion has renewed its European Medicines Agency (EMA) Good Manufacturing Practice (EU-GMP) certification for its drug substance and drug product production facilities at its Songdo campus. This renewal supports the company’s goal to increase total production volume at the site by approximately 15% this year, driven largely by its third plant which began commercial production in late 2024.

Concurrently, Daewoong Pharmaceutical has opened an advanced biopharmaceutical manufacturing facility at the Yonsei University International Campus in Songdo. This site is designed to produce stem cells and immune cell products for clinical research. The company intends to link this new facility with its existing Yongin Bio Center to bridge the gap between research and clinical application.

Entities

Ministry of Health and Welfare · European Medicines Agency · Songdo Bio Cluster · Samsung Biologics · Celltrion

Timeline

  1. [BUSINESS] 2 sources
    Daewoong Pharmaceutical opens advanced biopharmaceutical facility in Songdo

    Daewoong Pharmaceutical opened a new advanced biopharmaceutical manufacturing facility in Songdo to accelerate the clinical production of stem cell and immune cell therapies for incurable diseases.

  2. [BUSINESS] 6 sources
    Celltrion renews EU-GMP certification for Songdo production facilities

    Celltrion renewed EU-GMP certification for its Songdo facilities, aiming for a 15% production increase. Samsung Biologics is also expanding its Songdo capacity to reach 1.385 million liters.

Sources

biotimes.co.kr · biz.heraldcorp.com · joongboo.com · kormedi.com · newstomato.com · socialvalue.kr · thebionews.net